PURPOSE: The aim of the study was to assess the outcomes of severe @entity989 ( @entity989 ) in zone I or posterior zone II treated with intravitreal ranibizumab (IVR) as monotherapy or combined treatment with laser photocoagulation. METHODS: This is a retrospective study analyzing clinical records of the included @entity1 . @entity1 were divided into two groups: group 1 included @entity1 who received only IVR treatment; and group 2 was subdivided into group 2A - including @entity1 with IVR as initial treatment and complementary laser photocoagulation if @entity2479 or plus disease did not regress, and group 2B - including @entity1 with @entity1613 and IVR as rescue therapy. Favorable outcomes were @entity2479 and plus disease, meaning control of the disease. Unfavorable outcomes were progression to stages 4 and 5 of @entity989 . RESULTS: Fifty-seven eyes were included in the study. Mean birth weight and gestational age were 1,281  254 g and 29.5  2.1 weeks, respectively. Group 1 comprised of 16 eyes, with favorable outcomes in 14 eyes (87.5%). Group 2 comprised of 41 eyes, with favorable outcomes in 29 eyes (70.7%), in a mean follow-up period of 12.8 months. CONCLUSION: IVR was effective to treat severe cases of @entity989 as a primary or a combined treatment. Forty-three of the 57 treated eyes (75.4%) achieved regression of @entity989 and favorable outcomes.

Intravitreal ranibizumab as a primary or a combined treatment for severe XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal neovascularization', 'regression of the retinal neovascularization'] @entity1613 :: ('MESH:D011230', 'Disease') :: ['initial laser photocoagulation'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy of prematurity', 'ROP']
@entity989 :: (MESH:D012164,Disease) :: ['retinopathy of prematurity']
